Development of de novo donor-specific HLA antibodies and AMR in renal transplant patients...

Updated management for antibody-mediated rejection: opportunity to prolong kidney allograft survival

N Townamchai, Y Avihingsanon - Current Opinion in Nephrology …, 2023 - journals.lww.com

Updated management for antibody-mediated rejection: opportun... : Current Opinion in
Nephrology and Hypertension Updated management for antibody-mediated rejection …

被引用次数：6 相关文章所有 4 个版本

[HTML] nih.gov

Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers

KA Reininger, G Onyeaghala… - Clinical …, 2023 - Wiley Online Library

Kidney transplant recipients carrying the CYP3A5* 1 allele have lower tacrolimus troughs,
and higher dose requirements compared to those with the CYP3A5* 3/* 3 genotype …

被引用次数：5 相关文章所有 9 个版本

[PDF] wiley.com

Assessing the Utility of a Genotype‐Guided Tacrolimus Equation in African American Kidney Transplant Recipients: A Single Institution Retrospective Study

JE Obayemi, L Callans, N Nair, H Gao… - The Journal of …, 2024 - Wiley Online Library

Tacrolimus metabolism is heavily influenced by the CYP3A5 genotype, which varies widely
among African Americans (AA). We aimed to assess the performance of a published …

[HTML][HTML] Antibody-mediated Rejection in Kidney Transplant: An Unmastered Area

S Valavoor, M Anand, A Govil - Indian Journal of Transplantation, 2024 - journals.lww.com

Antibody-mediated rejection (ABMR) remains a significant cause of allograft failure in
patients with kidney transplantation. Despite successful strategies to treat ABMR, irreversible …

CYP3A5-Expression: Risiko-faktor für donorspezifi-sche Antikörper nach Nierentransplantation

KII HLA-Antikörper - Transfusion, 2022 - thieme-connect.com

„What would it take to convince you to donate?“Diese Frage stellten Psychologen den
Studienteilnehmern mit unterschiedlicher Spendengeschichte, in verschiedenen …